Alector Inc
ALEC1.505USD
+0.055+3.79%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
150.49MCap. mercado
PérdidaP/E TTM
Más Datos de Alector Inc Compañía
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The Company is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.
Información de la empresa
Símbolo de cotizaciónALEC
Nombre de la empresaAlector Inc
Fecha de salida a bolsaFeb 07, 2019
Director ejecutivoDr. Arnon Rosenthal, Ph.D.
Número de empleados238
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 07
Dirección131 Oyster Point Blvd., Suite 600
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Teléfono14152315660
Sitio Webhttps://alector.com
Símbolo de cotizaciónALEC
Fecha de salida a bolsaFeb 07, 2019
Director ejecutivoDr. Arnon Rosenthal, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Arnon Rosenthal, Ph.D.
Dr. Arnon Rosenthal, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
5.58M
+2.52%
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
President, Head - Research and Development
President, Head - Research and Development
156.08K
+53.99%
Dr. Kristine Yaffe
Dr. Kristine Yaffe
Independent Director
Independent Director
60.41K
+84.69%
Dr. Richard H. Scheller, Ph.D.
Dr. Richard H. Scheller, Ph.D.
Director
Director
56.41K
+103.58%
Dr. Paula Hammond, Ph.D.
Dr. Paula Hammond, Ph.D.
Independent Director
Independent Director
53.91K
+113.85%
Mr. Mark Altmeyer
Mr. Mark Altmeyer
Independent Director
Independent Director
39.01K
+278.29%
Mr. Giacomo Salvadore, M.D.
Mr. Giacomo Salvadore, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Louis J. (Lou) Lavigne, Jr.
Mr. Louis J. (Lou) Lavigne, Jr.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Errol De Souza, Ph.D.
Dr. Errol De Souza, Ph.D.
Independent Director
Independent Director
--
--
Dr. Elizabeth A. (Betsy) Garofalo, M.D.
Dr. Elizabeth A. (Betsy) Garofalo, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Arnon Rosenthal, Ph.D.
Dr. Arnon Rosenthal, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
5.58M
+2.52%
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
President, Head - Research and Development
President, Head - Research and Development
156.08K
+53.99%
Dr. Kristine Yaffe
Dr. Kristine Yaffe
Independent Director
Independent Director
60.41K
+84.69%
Dr. Richard H. Scheller, Ph.D.
Dr. Richard H. Scheller, Ph.D.
Director
Director
56.41K
+103.58%
Dr. Paula Hammond, Ph.D.
Dr. Paula Hammond, Ph.D.
Independent Director
Independent Director
53.91K
+113.85%
Mr. Mark Altmeyer
Mr. Mark Altmeyer
Independent Director
Independent Director
39.01K
+278.29%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 14 de may
Actualizado: mié., 14 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
14.39%
Polaris Venture Partners
9.85%
RA Capital Management, LP
9.70%
BlackRock Institutional Trust Company, N.A.
6.41%
The Vanguard Group, Inc.
6.05%
Other
53.59%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
14.39%
Polaris Venture Partners
9.85%
RA Capital Management, LP
9.70%
BlackRock Institutional Trust Company, N.A.
6.41%
The Vanguard Group, Inc.
6.05%
Other
53.59%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
34.87%
Venture Capital
21.09%
Investment Advisor/Hedge Fund
13.63%
Hedge Fund
8.42%
Individual Investor
7.06%
Corporation
3.55%
Research Firm
2.88%
Pension Fund
0.22%
Bank and Trust
0.08%
Other
8.20%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
372
91.63M
91.64%
-20.36M
2025Q1
390
94.05M
94.69%
-22.49M
2024Q4
384
95.68M
96.58%
-16.24M
2024Q3
380
93.59M
96.08%
-7.82M
2024Q2
378
93.92M
97.44%
-5.66M
2024Q1
379
96.98M
102.83%
+4.66M
2023Q4
382
85.51M
101.07%
-5.87M
2023Q3
384
84.61M
100.28%
-2.32M
2023Q2
384
80.93M
96.65%
-6.40M
2023Q1
391
80.04M
96.46%
-3.77M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
14.39M
14.39%
-299.63K
-2.04%
Mar 31, 2025
Polaris Venture Partners
9.85M
9.85%
--
--
Sep 30, 2024
RA Capital Management, LP
9.70M
9.7%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.41M
6.41%
-393.95K
-5.79%
Mar 31, 2025
The Vanguard Group, Inc.
6.05M
6.05%
+453.75K
+8.10%
Mar 31, 2025
Rosenthal (Arnon)
5.44M
5.44%
-52.09K
-0.95%
Jun 02, 2025
Merck & Co Inc
3.55M
3.55%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.96M
1.96%
+47.85K
+2.50%
Mar 31, 2025
State Street Global Advisors (US)
1.64M
1.64%
-209.03K
-11.30%
Mar 31, 2025
J.P. Morgan Securities LLC
1.45M
1.45%
-159.71K
-9.94%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.47%
iShares Neuroscience and Healthcare ETF
0.27%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Biotechnology ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 ETF
0%
Fidelity MSCI Health Care Index ETF
0%
JPMorgan Fundamental Data Science Small Core ETF
0%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.47%
iShares Neuroscience and Healthcare ETF
Proporción0.27%
iShares Micro-Cap ETF
Proporción0.03%
Invesco Nasdaq Biotechnology ETF
Proporción0.02%
ProShares Ultra Nasdaq Biotechnology
Proporción0.02%
iShares Biotechnology ETF
Proporción0.01%
iShares Russell 2000 Value ETF
Proporción0.01%
iShares Russell 2000 ETF
Proporción0%
Fidelity MSCI Health Care Index ETF
Proporción0%
JPMorgan Fundamental Data Science Small Core ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
